期刊
EXPERT REVIEW OF VACCINES
卷 13, 期 3, 页码 387-398出版社
EXPERT REVIEWS
DOI: 10.1586/14760584.2014.880340
关键词
4-1BB; adjuvants; cancer vaccines; CD137; costimulation; SA-4-1BBL
类别
资金
- NIH [R43 CA 109866, R43 AI071618, R41 CA121665]
- Kentucky Science and Technology Corporation
- Kentucky Lung Cancer Research Program
- James Brown, Cancer Center Research Fellowship
- W.M. Keck Foundation
- Commonwealth of Kentucky Research Challenge Trust Fund
Tumor associated antigen (TAA)-based therapeutic vaccines have great potential as a safe, practical, and cost-efficient alternative to standard treatments for cancer. Clinical efficacy of TAA-based vaccines, however, has yet to be realized and will require adjuvants with pleiotropic functions on immune cells. Such adjuvants need not only to generate/boost T cell responses, but also reverse intrinsic/extrinsic tumor immune evasion mechanisms for therapeutic efficacy. This review focuses on a novel agonistic ligand, SA-4-1BBL, for 4-1BB costimulatory receptor as an adjuvant of choice because of its ability to: i) serve as a vehicle to deliver TAAs to dendritic cells (DCs) for antigen uptake and cross-presentation to CD8(+) T cells; ii) augment adaptive Th1 and innate immune responses; and iii) overcome various immune evasion mechanisms, cumulatively translating into therapeutic efficacy in preclinical tumor models.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据